Diarrhea is a clinically significant complication in patients with advanced medullary thyroid carcinoma (MTC). This page addresses the management approach for this specific clinical scenario.
This protocol applies to patients with advanced MTC presenting with diarrhea. Diarrhea occurs most frequently in patients with advanced disease and hepatic metastases, and is a common occurrence in patients with advanced MTC and markedly elevated serum Ctn levels.
Management in this setting may involve somatostatin analogs — the complete structured protocol details the full range of interventions and decision points applicable to this presentation.
DOI: 10.1089/thy.2014.0335
Diarrhea occurs most frequently in patients with advanced disease and hepatic metastases.
Diarrhea is a common occurrence in patients with advanced MTC and markedly elevated serum Ctn levels.
Alternative therapies include somatostatin analogs and local therapies such as surgery or chemoembolization.
Treatment with somatostatin analogs and debulking of large tumors has also been employed.
View source ↗